NCT01159756

To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 468 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a multi-site, unmasked phase IV study. Travacom(R) is a combination topical ocular agent, containing travoprost and timolol, which lower intraocular pressure (IOP) by complementary mechanisms of action. The safety and efficacy of both travoprost and timolol have been established as single and adjunctive therapy in well-controlled clinical studies in thousands of patients diagnosed with open angle glaucoma (OAG) or ocular hypertension. The objective of this study is to assess the safety and efficacy of changing to Travacom from prior pharmacotherapy in uncontrolled patients with open-angled glaucoma or ocular hypertension across India.

Conditions

• Uncontrolled Intraocular Pressure

Interventions

Type	Name	Description
DRUG	Travacom	Travacom ophthalmic solution (1 drop per day)

Timeline

• Start date: 2010-07-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2010-07-09
• Last updated: 2012-04-10

Locations

1 site across 1 country: India